Abstract
Background and aims: A reliable non-invasive assessment of the severity of diffuse liver disease is much needed. We investigated the utility of hepatic vein transit times (HVTT) for grading and staging diffuse liver disease in a cohort of patients with hepatitis C virus (HCV) infection using an ultrasound microbubble contrast agent as a tracer.
Materials and methods: Eighty five untreated patients with biopsy proven HCV induced liver disease were studied prospectively. All were HCV RNA positive on polymerase chain reaction testing. Based on their histological fibrosis (F) and necroinflammatory (NI) scores, untreated patients were divided into mild hepatitis (F less than or equal to2/6, NI less than or equal to3/18), moderate/ severe hepatitis (3 less than or equal toF 10% above baseline. The Doppler signals from the carotid artery were also measured in 60 patients and carotid delay times (CDT) calculated as the difference between carotid and hepatic vein arrival times. The earliest HVTT in each patient was used for analysis.
Results: Mean (SEM) HVTT for the control, mild hepatitis, moderate/ severe hepatitis, and cirrhosis groups showed a monotonic decrease of 38.1 (2.8), 38.8 (2.4), 26.0 (2.4), and 15.8 (0.8) seconds, respectively. Mean (SEM) CDT for the control, mild hepatitis, moderate/ severe hepatitis, and cirrhosis patients again showed progressive shortening of 30.3 (2.6), 25.9 (2.6), 14.8 (2.1), and 5.6 (1.2) seconds, respectively. There were significant differences between the groups for HVTT (ANOVA, p
Conclusion: We have shown, for the first time, that HVTT using an ultrasound microbubble contrast agent can assess HCV related liver disease with clear differentiation between mild hepatitis and cirrhosis. There were significant differences between these two groups and the moderate/ severe hepatitis group. CDT offers no additional benefit or greater differentiation than HVTT and can be omitted, thus simplifying this technique. HVTT may complement liver biopsy and may also be a useful alternative for assessment of liver disease in patients who have contraindications to biopsy.
Original language | English |
---|---|
Pages (from-to) | 128-133 |
Number of pages | 6 |
Journal | Gut |
Volume | 54 |
Issue number | 1 |
DOIs | |
Publication status | Published - Jan 2005 |
Keywords
- DIFFUSE LIVER-DISEASE
- ULTRASOUND CONTRAST AGENT
- BIOCHEMICAL MARKERS
- FIBROSIS
- DIAGNOSIS
- ULTRASONOGRAPHY
- CIRRHOSIS
- BIOPSY
- AUDIT
- INDEX